Abstract
Objective To investigate the relationship between CYP2C19 gene polymorphisms and clopidogrel efficacy in coronary heart disease patients after percutaneous coronary intervention (PCI). Methods From January 2016 to December 2017, 62 patients with acute coronary syndromes and treated with PCI in Guizhou Aerospace Hospital were recruited, CYP2C19 genotype, ADP-induced platelet aggregation rate and myocardial enzymes and other indicators were detected before operation.The myocardial enzymes were measured 24 hours after PCI.According to different metabolic types, the patients were grouped, the above indicators were compared. Results The CYP2C19*1/*1 was 37.10%, CYP2C19*1/*2 was 35.48%, CYP2C19*1/*3 was 11.29%, CYP2C19*2/*2 was 12.90%, CYP2C19*2/*3 was 3.23% and CYP2C19*3/*3 was 0.00%.The LDH, AST, CK, CK-MB and α-HBDH in the PCI patients after operation were significantly higher than those before operation(t=0.019, 0.040, 0.044, 0.022, 0.014, all P 0.05). Conclusion CYP2C19 mutation frequency in the Chinese population is relatively large, the sample size of this study is less, the relationship between clopidogrel resistance and the specific genotype can not be obtained, it need to increase the sample size and comprehensive multi-factor consideration. Key words: Percutaneous coronary intervention; Gentype; Cytochrome P-450; Clopidogrel
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
